129-03-3
129-03-3
Chemical Structure
Cyproheptadine
- CAS No.: 129-03-3
- Formula:C21H21N
- Molecular Weight:287.40
IUPAC Name: 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
InChIKey: JJCFRYNCJDLXIK-UHFFFAOYSA-N
SMILES: CN1CC/C(CC1)=C2C3=CC=CC=C3C=CC4=CC=CC=C/24
Biological Activity: Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cyproheptadine | 99.92% | Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cyproheptadine (Standard) | ≥98% | Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cyproheptadine-d3 | Cyproheptadine-d3 is deuterium labeled Cyproheptadine. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Iwaki M, et al. Pharmacokinetics of cyproheptadine and its metabolites in rats. Biol Pharm Bull. 1993 Dec;16(12):1276-81. [Content Brief]
- [2]. Codd EE, et al. Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine. Toxicol Sci. 2010 Oct;117(2):493-504. [Content Brief]
